[go: up one dir, main page]

WO2002064124A3 - Medicament formulation containing a muscarinic agonist - Google Patents

Medicament formulation containing a muscarinic agonist Download PDF

Info

Publication number
WO2002064124A3
WO2002064124A3 PCT/EP2002/001374 EP0201374W WO02064124A3 WO 2002064124 A3 WO2002064124 A3 WO 2002064124A3 EP 0201374 W EP0201374 W EP 0201374W WO 02064124 A3 WO02064124 A3 WO 02064124A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulation containing
muscarinic agonist
medicament formulation
muscarinic
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/001374
Other languages
German (de)
French (fr)
Other versions
WO2002064124A2 (en
Inventor
Thomas Friedl
Karoline Bechtold-Peters
Michael Walz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to JP2002563919A priority Critical patent/JP2004518710A/en
Priority to MXPA03007272A priority patent/MXPA03007272A/en
Priority to AU2002247705A priority patent/AU2002247705A1/en
Priority to EP02716755A priority patent/EP1361871A2/en
Priority to CA002434976A priority patent/CA2434976A1/en
Publication of WO2002064124A2 publication Critical patent/WO2002064124A2/en
Publication of WO2002064124A3 publication Critical patent/WO2002064124A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The invention relates to a novel medicament formulation containing the muscarinic agonist talsaclidine and to a method for the production thereof.
PCT/EP2002/001374 2001-02-15 2002-02-09 Medicament formulation containing a muscarinic agonist Ceased WO2002064124A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002563919A JP2004518710A (en) 2001-02-15 2002-02-09 Pharmaceutical formulations containing muscarinic agonists
MXPA03007272A MXPA03007272A (en) 2001-02-15 2002-02-09 Medicament formulation containing a muscarinic agonist.
AU2002247705A AU2002247705A1 (en) 2001-02-15 2002-02-09 Medicament formulation containing a muscarinic agonist
EP02716755A EP1361871A2 (en) 2001-02-15 2002-02-09 Medicament formulation containing a muscarinic agonist
CA002434976A CA2434976A1 (en) 2001-02-15 2002-02-09 Medicament formulation containing a muscarinic agonist

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10106971A DE10106971A1 (en) 2001-02-15 2001-02-15 Drug formulation containing a muscarinic agonist
DE10106971.5 2001-02-15

Publications (2)

Publication Number Publication Date
WO2002064124A2 WO2002064124A2 (en) 2002-08-22
WO2002064124A3 true WO2002064124A3 (en) 2002-12-05

Family

ID=7674095

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001374 Ceased WO2002064124A2 (en) 2001-02-15 2002-02-09 Medicament formulation containing a muscarinic agonist

Country Status (9)

Country Link
EP (1) EP1361871A2 (en)
JP (1) JP2004518710A (en)
AR (1) AR033862A1 (en)
AU (1) AU2002247705A1 (en)
CA (1) CA2434976A1 (en)
DE (1) DE10106971A1 (en)
MX (1) MXPA03007272A (en)
UY (1) UY27170A1 (en)
WO (1) WO2002064124A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149532B2 (en) 2007-03-29 2015-10-06 Daiichi Sanykyo Company, Limited Pharmaceutical composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
CA2793525C (en) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
ES2673182T3 (en) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Pharmaceutical composition containing a diamine derivative

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370415A1 (en) * 1988-11-22 1990-05-30 Boehringer Ingelheim Kg Quinuclidines, their pharmaceutical use and process for their preparation
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
WO1998046601A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
WO1998046225A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Method for treating schizophrenia
DE19851126A1 (en) * 1998-11-06 2000-05-11 Boehringer Ingelheim Pharma Use of talsaclidine for treating schizophrenia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370415A1 (en) * 1988-11-22 1990-05-30 Boehringer Ingelheim Kg Quinuclidines, their pharmaceutical use and process for their preparation
WO1998030243A1 (en) * 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
WO1998046601A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
WO1998046225A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Method for treating schizophrenia
DE19851126A1 (en) * 1998-11-06 2000-05-11 Boehringer Ingelheim Pharma Use of talsaclidine for treating schizophrenia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149532B2 (en) 2007-03-29 2015-10-06 Daiichi Sanykyo Company, Limited Pharmaceutical composition

Also Published As

Publication number Publication date
AR033862A1 (en) 2004-01-07
EP1361871A2 (en) 2003-11-19
CA2434976A1 (en) 2002-08-22
AU2002247705A1 (en) 2002-08-28
JP2004518710A (en) 2004-06-24
MXPA03007272A (en) 2003-12-04
WO2002064124A2 (en) 2002-08-22
DE10106971A1 (en) 2002-08-29
UY27170A1 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
AU2002313236A1 (en) Medicinal compositions
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
AU2002213977A1 (en) Novel anticholinergics, method for the production thereof and use thereof as medicaments
AU2002302147A1 (en) Pharmaceutical composition
AU2002364342A1 (en) Heteroxylan film-forming composition for making capsules and resulting capsules
AU2002309038A1 (en) Compositions for transmucosal administration containing coenzyme Q as the active ingredient
AU2002337158A1 (en) Method for the production of adhesive stamped products
AU2003286944A1 (en) Crude drug compositions and the process for preparing them
AU2002210632A1 (en) Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same
AU3825700A (en) Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
WO2002064124A3 (en) Medicament formulation containing a muscarinic agonist
AU2002233563A1 (en) Plant composition for smoking
AU2003302320A1 (en) Seterocyclic quinones as pharmaceutical agents
AU2002218494A1 (en) Medicinal compositions and process for producing the same
AU2002354460A1 (en) Medicinal composition
AU2002223617A1 (en) Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds
AU2001231676A1 (en) Substituted phenylamidines medicaments containing said compounds and method for production thereof
AUPR529701A0 (en) Pharmaceutical composition
AU2002346223A1 (en) Medicinal compositions
AU2002361987A1 (en) Substituted beta-aminoalcohols used as medicaments
AU2002242962A1 (en) Isoquinuclidine derivative, process for producing the same, and medicinal composition containing the same
AU2002330476A1 (en) Medicinal compositions for diabetic neuropathy
AU2002308066A1 (en) Pharmaceutical composition containing bulbophyllum
AU2002257876A1 (en) Tetrahydropyridyl-alkyl-heterocycles, method for preparing same and pharmaceutical compositions containing same
AU2002100921A4 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002716755

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2434976

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002563919

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007272

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 2002716755

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002716755

Country of ref document: EP